In psoriasis patients treated with the JAK1/2 inhibitor baricitinib or the TNFα antagonist etanercept, IL-19 levels were also highly correlated with PASI scores, and decreases correlated with PASI improvement. This evidence concerns the gene IL19 and psoriasis.